Tryptophan pathway metabolites as prognostic biomarkers of recurrent disease in curatively operated neuroendocrine tumor patients

#4248

Introduction: The majority of NET patients experience recurrent disease after curative surgery. There is a need for prognostic biomarkers in this patient group.

Aim(s): Our aim is to evaluate the potential of plasma tryptophan metabolites to predict disease recurrence in curatively operated NET patients.

Materials and methods: We included patients with well-differentiated locoregional NET from 2016-2022 at the University Hospital North Norway, Tromsø. All patients were operated with curative intent. Plasma samples were done at inclusion and analysed by liquid chromatography tandem mass spectrometry and 8 different tryptophan metabolites were quantified.

Conference:

Presenting Author: Johansen S

Authors: Johansen S, Hansen T, Goll R, Florholmen J,

Keywords: Plasma Tryptophan Metabolites, Prognostic Biomarker, Recurrent Disease after Curative Surgery,